These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 22300720)
21. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America. Giglio N; Micone P; Gentile A Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351 [TBL] [Abstract][Full Text] [Related]
22. Vaccine supply: a cross-national perspective. Danzon PM; Pereira NS; Tejwani SS Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165 [TBL] [Abstract][Full Text] [Related]
23. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993 [TBL] [Abstract][Full Text] [Related]
24. Tailoring the strategies to specific shortages: pneumococcal conjugate vaccine. Peter G Clin Infect Dis; 2006 Mar; 42 Suppl 3():S138-40. PubMed ID: 16447136 [TBL] [Abstract][Full Text] [Related]
25. Vaccines as a global imperative--a business perspective. Stéphenne J Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955 [TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic. Dhankhar P; Grabenstein JD; O'Brien MA; Dasbach EJ Clin Ther; 2010 Aug; 32(8):1501-16. PubMed ID: 20728763 [TBL] [Abstract][Full Text] [Related]
30. Casting off vaccine supply charity -- the pace quickens. CVI goal: quality vaccines for all children. CVI Forum; 1995 Oct; (10):9-13. PubMed ID: 12290725 [TBL] [Abstract][Full Text] [Related]
31. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Jacobs RJ; Meyerhoff AS Prev Med; 2001 Dec; 33(6):639-45. PubMed ID: 11716661 [TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641 [TBL] [Abstract][Full Text] [Related]
34. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Talbird SE; Taylor TN; Knoll S; Frostad CR; García Martí S Vaccine; 2010 Nov; 28 Suppl 6():G23-9. PubMed ID: 21075266 [TBL] [Abstract][Full Text] [Related]
35. Temporary vaccine recommendations and provider compliance: a survey of pediatric practices during the 2003-2004 pneumococcal conjugate vaccine shortage. Groom H; Bhatt A; Washington ML; Santoli J Pediatrics; 2008 Oct; 122(4):e835-40. PubMed ID: 18829781 [TBL] [Abstract][Full Text] [Related]